Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2022
Event: Execution of a Settlement and License Agreement with BGI Genomics Technology Co., Ltd. and related entities (collectively "BGI").
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial impact disclosed is a specific settlement payment.
- Settlement Payment: Illumina agreed to pay Complete Genomics a one-time payment of $325 million.
- License Value: The filing does not assign a specific monetary value to the patent licenses exchanged, noting only that they are "fully paid-up."
Material Changes and Litigation Resolution
The Agreement resolves multiple pending litigations between Illumina and BGI, including:
- Patent Disputes: Resolves claims in Complete Genomics, Inc. v. Illumina, Inc. (D. Del.) and two cases in the Northern District of California, along with related Federal Circuit appeals.
- Antitrust Claims: Resolves all antitrust claims in Complete Genomics, Inc., BGI Americas Corp. and MGI Americas, Inc. v. Illumina, Inc. (N.D. Cal.), resulting in the dismissal of the complaint with prejudice.
- Injunction Status: The permanent injunction entered on April 11, 2022, against BGI remains in effect regarding BGI's StandardMPS chemistry, with a revised expiration date of January 1, 2023.
Guidance, Outlook, and Intellectual Property Terms
Intellectual Property Exchange:
- Illumina Received: A fully paid-up license to specific U.S. patents and applications related to "2-channel technology." This license covers all current and future platforms with no additional royalties owed.
- BGI Received: A fully paid-up license to specific U.S. patents and applications related to "image mix patents."
Future Litigation Standstill:
- Parties agreed to a litigation standstill for patent and antitrust actions in the U.S. and its territories until October 1, 2025.
- Exclusions: The standstill does not apply to patents related to non-invasive prenatal testing (NIPT) or intellectual property of Grail, Inc. related to multi-cancer early detection.
- Liability: No party made an admission of liability.
Investor Verification Checklist
- Verify the impact of the $325 million one-time payment on the company's current quarter cash flow and earnings.
- Confirm the strategic value of the acquired "2-channel technology" patents for future platform development.
- Monitor the status of the permanent injunction against BGI's StandardMPS chemistry expiring January 1, 2023.
- Review the scope of the litigation standstill to ensure it adequately protects interests in NIPT and Grail-related multi-cancer early detection technologies.